DKK171.60
1.15% yesterday
Copenhagen, Sep 27, 04:59 pm CET
ISIN
DK0061802139
Symbol
ALK B
Sector
Industry

ALK-Abelló Stock price

DKK171.60
-9.20 5.09% 1M
+47.50 38.28% 6M
+70.40 69.57% YTD
+91.40 113.97% 1Y
+30.70 21.79% 3Y
+102.05 146.73% 5Y
+135.90 380.67% 10Y
Copenhagen, Closing price Fri, Sep 27 2024
-2.00 1.15%
ISIN
DK0061802139
Symbol
ALK B
Sector
Industry

Key metrics

Market capitalization DKK38.42b
Enterprise Value DKK38.51b
P/E (TTM) P/E ratio 55.66
EV/FCF (TTM) EV/FCF 49.88
EV/Sales (TTM) EV/Sales 7.43
P/S ratio (TTM) P/S ratio 7.42
P/B ratio (TTM) P/B ratio 7.81
Revenue growth (TTM) Revenue growth 10.68%
Revenue (TTM) Revenue DKK5.18b
EBIT (operating result TTM) EBIT DKK916.00m
Free Cash Flow (TTM) Free Cash Flow DKK772.00m
Cash position DKK420.00m
EPS (TTM) EPS DKK3.12
P/E forward 44.46
P/S forward 6.95
EV/Sales forward 6.96
Show more

Is ALK-Abelló a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

ALK-Abelló Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a ALK-Abelló forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a ALK-Abelló forecast:

Buy
71%
Hold
29%

Financial data from ALK-Abelló

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
5,180 5,180
11% 11%
100%
- Direct Costs 1,895 1,895
7% 7%
37%
3,285 3,285
13% 13%
63%
- Selling and Administrative Expenses 1,556 1,556
5% 5%
30%
- Research and Development Expense 555 555
16% 16%
11%
1,174 1,174
52% 52%
23%
- Depreciation and Amortization 258 258
6% 6%
5%
EBIT (Operating Income) EBIT 916 916
73% 73%
18%
Net Profit 690 690
92% 92%
13%

In millions DKK.

Don't miss a Thing! We will send you all news about ALK-Abelló directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. The firm manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. The company was founded by Poul Christian Krejner Tejn Barfod on June 9, 1923 and is headquartered in Horsholm, Denmark.

Head office Denmark
CEO Peter Halling
Employees 2,824
Founded 1923
Website www.alk.net

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today